Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance

Science Signaling

Volumn 7, Issue 313, 2014, Pages

  Farren, Matthew R ^a   Carlson, Louise M ^a   Netherby, Colleen S ^a   Lindner, Inna ^b,e   Li, Pui Kai ^c   Gabrilovich, Dmitry I ^d   Abrams, Scott I ^a   Lee, Kelvin P ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d WISTAR INSTITUTE   (United States)

^e DeVry Medical International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BREAST NEOPLASMS; DENDRITIC CELLS; FEMALE; HUMANS; K562 CELLS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MYELOID PROGENITOR CELLS; NEOPLASM PROTEINS; PROTEIN KINASE C BETA; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84894274842     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004656     Document Type: Article

References (57)

1. J. Banchereau, F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, K. Palucka, Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767- 811 (2000).
2. S. Gallucci, P. Matzinger, Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13, 114-119 (2001).
3. W. R.Heath,G. T. Belz,G.M.Behrens, C. M. Smith, S. P.Forehan, I. A.Parish, G. M. Davey, N. S.Wilson, F. R. Carbone, J. A. Villadangos, Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199, 9-26 (2004).
4. D. Gabrilovich, Mechanisms and functional significance of tumour-induced dendriticcell defects. Nat. Rev. Immunol. 4, 941-952 (2004).
5. M. Camus, M. Tosolini, B. Mlecnik, F. Pagès, A. Kirilovsky, A. Berger, A. Costes, G. Bindea, P. Charoentong, P. Bruneval, Z. Trajanoski, W. H. Fridman, J. Galon, Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 69, 2685-2693 (2009).
6. R. J. McKallip, M. Nagarkatti, P. S. Nagarkatti, Δ-9- Tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol. 174, 3281-3289 (2005).
7. M. C. Dieu-Nosjean, M. Antoine, C. Danel, D. Heudes, M. Wislez, V. Poulot, N. Rabbe, L. Laurans, E. Tartour, L. de Chaisemartin, S. Lebecque, W. H. Fridman, J. Cadranel, Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26, 4410-4417 (2008).
8. M. Collin, V. Bigley, M. Haniffa, S. Hambleton, Human dendritic cell deficiency: The missing ID? Nat. Rev. Immunol. 11, 575-583 (2011).
9. F. Ghiringhelli, L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma, C. Ortiz, K. Vermaelen, T. Panaretakis, G. Mignot, E. Ullrich, J. L. Perfettini, F. Schlemmer, E. Tasdemir, M. Uhl, P. Génin, A. Civas, B. Ryffel, J. Kanellopoulos, J. Tschopp, F. André, R. Lidereau, N. M. McLaughlin, N. M. Haynes, M. J. Smyth, G. Kroemer, L. Zitvogel, Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 15, 1170-1178 (2009).
10. D. I. Gabrilovich, S. Ostrand-Rosenberg, V. Bronte, Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268 (2012).
11. T. F. Greten, M. P. Manns, F. Korangy, Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol. 11, 802-807 (2011).
12. A. J. Montero, C. M. Diaz-Montero, C. E. Kyriakopoulos, V. Bronte, S. Mandruzzato, Myeloid-derived suppressor cells in cancer patients: A clinical perspective. J. Immunother. 35, 107-115 (2012).
13. J. D. Waight, Q. Hu, A. Miller, S. Liu, S. I. Abrams, Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLOS One 6, e27690 (2011).
14. M. Kortylewski, R. Jove, H. Yu, Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev. 24, 315-327 (2005).
15. M. Kortylewski, M. Kujawski, T. Wang, S. Wei, S. Zhang, S. Pilon-Thomas, G. Niu, H. Kay, J. Mulé, W. G. Kerr, R. Jove, D. Pardoll, H. Yu, Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11, 1314- 1321 (2005).
16. C. A. Corzo, M. J. Cotter, P. Cheng, F. Cheng, S. Kusmartsev, E. Sotomayor, T. Padhya, T. V. McCaffrey, J. C. McCaffrey, D. I. Gabrilovich, Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 182, 5693-5701 (2009).
17. D. I. Gabrilovich, S. Nagaraj, Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174 (2009).
18. D. Vasquez-Dunddel, F. Pan, Q. Zeng, M. Gorbounov, E. Albesiano, J. Fu, R. L. Blosser, A. J. Tam, T. Bruno, H. Zhang, D. Pardoll, Y. Kim, STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J. Clin. Invest. 123, 1580-1589 (2013).
19. P. J. Cejas, L. M. Carlson, J. Zhang, S. Padmanabhan, D. Kolonias, I. Lindner, S. Haley, L. H. Boise, K. P. Lee, Protein kinase C βII plays an essential role in dendritic cell differentiation and autoregulates its own expression. J. Biol. Chem. 280, 28412-28423 (2005).
20. W. S. Liu, C. A. Heckman, The sevenfold way of PKC regulation. Cell. Signal. 10, 529- 542 (1998).
21. + monocyte differentiation towards macrophages and dendritic cells, respectively. J. Cell. Biochem. 102, 429-441 (2007).
22. W. C. Hooper, R. T. Abraham, C. L. Ashendel, G. E. Woloschak, Differential responsiveness to phorbol esters correlates with differential expression of protein kinase C in KG-1 and KG-1a human myeloid leukemia cells. Biochim. Biophys. Acta 1013, 47-54 (1989).
23. I. Marigo, E. Bosio, S. Solito, C. Mesa, A. Fernandez, L. Dolcetti, S. Ugel, N. Sonda, S. Bicciato, E. Falisi, F. Calabrese, G. Basso, P. Zanovello, E. Cozzi, S. Mandruzzato, V. Bronte, Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity 32, 790-802 (2010).
24. I. Lindner, M. A. Kharfan-Dabaja, E. Ayala, D. Kolonias, L. M. Carlson, Y. Beazer-Barclay, U. Scherf, J. H. Hnatyszyn, K. P. Lee, Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL. J. Immunol. 171, 1780-1791 (2003).
25. L. Burkly, C. Hession, L. Ogata, C. Reilly, L. A. Marconi, D. Olson, R. Tizard, R. Cate, D. Lo, Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 373, 531-536 (1995).
26. D. Carrasco, R. P. Ryseck, R. Bravo, Expression of rel B transcripts during lymphoid organ development: Specific expression in dendritic antigen-presenting cells. Development 118, 1221-1231 (1993).
27. A. R. Pettit, C. Quinn, K. P. MacDonald, L. L. Cavanagh, G. Thomas, W. Townsend, M. Handel, R. Thomas, Nuclear localization of RelB is associated with effective antigen-presenting cell function. J. Immunol. 159, 3681-3691 (1997).
28. J. Xie, J. Qian, J. Yang, S. Wang, M. E. Freeman III, Q. Yi, Critical roles of Raf/MEK/ ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells. Exp. Hematol. 33, 564-572 (2005).
29. K. Saijo, I. Mecklenbräuker, A. Santana, M. Leitger, C. Schmedt, A. Tarakhovsky, Protein kinase Cβ controls nuclear factor κB activation in B cells through selective regulation of the IκB kinase α. J. Exp. Med. 195, 1647-1652 (2002).
30. R. L. Stariha, S. U. Kim, Protein kinase C and mitogen-activated protein kinase signalling in oligodendrocytes. Microsc. Res. Tech. 52, 680-688 (2001).
31. U. Trollér, R. Zeidman, K. Svensson, C. Larsson, A PKCβ isoform mediates phorbol ester-induced activation of Erk1/2 and expression of neuronal differentiation genes in neuroblastoma cells. FEBS Lett. 508, 126-130 (2001).
32. P. J. Cejas, L. M. Carlson, D. Kolonias, J. Zhang, I. Lindner, D. D. Billadeau, L. H. Boise, K. P. Lee, Regulation of RelB expression during the initiation of dendritic cell differentiation. Mol. Cell. Biol. 25, 7900-7916 (2005).
33. G. D. Bren, N. J. Solan, H. Miyoshi, K. N. Pennington, L. J. Pobst, C. V. Paya, Transcription of the RelB gene is regulated by NF-κB. Oncogene 20, 7722-7733 (2001).
34. M. Hiasa, M. Abe, A. Nakano, A. Oda, H. Amou, S. Kido, K. Takeuchi, K. Kagawa, K. Yata, T. Hashimoto, S. Ozaki, K. Asaoka, E. Tanaka, K. Moriyama, T. Matsumoto, GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-α converting enzyme (TACE). Blood 114, 4517-4526 (2009).
35. C. E. Chalfant, J. E.Watson, L. D. Bisnauth, J. B. Kang, N. Patel, L. M. Obeid, D. C. Eichler, D. R. Cooper, Insulin regulates protein kinase CßII expression through enhanced exon inclusion in L6 skeletal muscle cells. A novel mechanism of insulin- and insulin-like growth factor-I-induced 5′ splice site selection. J. Biol. Chem. 273, 910- 916 (1998).
36. P. Ramadoss, N. E. Unger-Smith, F. S. Lam, A. N. Hollenberg, STAT3 targets the regulatory regions of gluconeogenic genes in vivo. Mol. Endocrinol. 23, 827-837 (2009).
37. P. Ravishankaran, R. Karunanithi, Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J. Surg. Oncol. 9, 18 (2011).
38. + T cells from patients with GI malignancy. Cancer Immunol. Immunother. 60, 1269-1279 (2011).
39. M. A. Bill, J. R. Fuchs, C. Li, J. Yui, C. Bakan, D. M. Benson Jr., E. B. Schwartz, D. Abdelhamid, J. Lin, D. G. Hoyt, S. L. Fossey, G. S. Young, W. E. Carson III, P. K. Li, G. B. Lesinski, The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with antitumor activity. Mol. Cancer 9, 165 (2010).
40. J. E. Darnell Jr., STATs and gene regulation. Science 277, 1630-1635 (1997).
41. T. Heinemeyer, E. Wingender, I. Reuter, H. Hermjakob, A. E. Kel, O. V. Kel, E. V. Ignatieva, E. A. Ananko, O. A. Podkolodnaya, F. A. Kolpakov, N. L. Podkolodny, N. A. Kolchanov, Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res. 26, 362-367 (1998).
42. T. Vincze, J. Posfai, R. J. Roberts, NEBcutter: A program to cleave DNA with restriction enzymes. Nucleic Acids Res. 31, 3688-3691 (2003).
43. N. Geijsen, M. Spaargaren, J. A. Raaijmakers, J.W. Lammers, L. Koenderman, P. J. Coffer, Association of RACK1 and PKCβ with the common β-chain of the IL-5/IL-3/GM-CSF receptor. Oncogene 18, 5126-5130 (1999).
44. S. N. Mattagajasingh, X. P. Yang, K. Irani, I. Mattagajasingh, L. C. Becker, Activation of Stat3 in endothelial cells following hypoxia-reoxygenation is mediated by Rac1 and protein kinase C. Biochim. Biophys. Acta 1823, 997-1006 (2012).
45. C. E. Chalfant, H. Mischak, J. E. Watson, B. C. Winkler, J. Goodnight, R. V. Farese, D. R. Cooper, Regulation of alternative splicing of protein kinase Cβ by insulin. J. Biol. Chem. 270, 13326-13332 (1995).
46. F. Basolo, P. G. Conaldi, L. Fiore, S. Calvo, A. Toniolo, Normal breast epithelial cells produce interleukins 6 and 8 together with tumor-necrosis factor: Defective IL6 expression in mammary carcinoma. Int. J. Cancer 55, 926-930 (1993).
47. J. J. Chiu, M. K. Sgagias, K. H. Cowan, Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin. Cancer Res. 2, 215-221 (1996).
48. I. Fricke, N. Mirza, J. Dupont, C. Lockhart, A. Jackson, J. H. Lee, J. A. Sosman, D. I. Gabrilovich, Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 13, 4840-4848 (2007).
49. D. Ron, D. Mochly-Rosen, Agonists and antagonists of protein kinase C function, derived from its binding proteins. J. Biol. Chem. 269, 21395-21398 (1994).
50. J. R. Graff, A. M. McNulty, K. R. Hanna, B. W. Konicek, R. L. Lynch, S. N. Bailey, C. Banks, A. Capen, R. Goode, J. E. Lewis, L. Sams, K. L. Huss, R. M. Campbell, P. W. Iversen, B. L. Neubauer, T. J. Brown, L. Musib, S. Geeganage, D. Thornton, The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 65, 7462-7469 (2005).
51. A. Z. Dudek, P. Zwolak, P. Jasinski, K. Terai, N. J. Gallus, M. E. Ericson, F. Farassati, Protein kinase C-β inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Invest. New Drugs 26, 13-24 (2008).
52. M. Clemons, A. A. Joy, R. Abdulnabi, M. Kotliar, J. Lynch, J. P. Jordaan, N. Iscoe, K. Gelmon, Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy. Breast Cancer Res. Treat. 124, 177-186 (2010).
53. C. B. Ambrosone, M. K. Nesline, W. Davis, Establishing a cancer center data bank and biorepository for multidisciplinary research. Cancer Epidemiol. Biomarkers Prev. 15, 1575-1577 (2006).
54. J. F. Bromberg, M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. Albanese, J. E. Darnell Jr., Stat3 as an oncogene. Cell 98, 295-303 (1999).
55. A. Kaptein, V. Paillard, M. Saunders, Dominant negative Stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction. J. Biol. Chem. 271, 5961-5964 (1996).
56. G. B. Lesinski, S. V. Kondadasula, T. Crespin, L. Shen, K. Kendra, M.Walker,W. E. Carson III, Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon alfa immunotherapy. J. Natl. Cancer Inst. 96, 1331-1342 (2004).
57. J.R. Nair, L. M. Carlson, C. Koorella, C. H. Rozanski, G. E. Byrne, P. L. Bergsagel, J. P. Shaughnessy Jr., L. H. Boise, A. Chanan-Khan, K. P. Lee, CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J. Immunol. 187, 1243-1253 (2011).